PLUS THERAPEUTICS, Inc. - Common Stock (PSTV)
1.2801
+0.0001 (0.01%)
Plus Therapeutics Inc is a biotechnology company focused on developing innovative therapies for cancer treatment
The company utilizes a proprietary nanoscale particle technology aimed at delivering targeted, localized therapies to improve patient outcomes while minimizing systemic side effects. Their pipeline includes treatments designed to address various types of cancer, with a particular emphasis on rare and hard-to-treat indications. Through its research and development efforts, Plus Therapeutics is committed to advancing the science of cancer care and providing new options for patients facing challenging diagnoses.
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 7, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 30, 2024
![](https://cdn.benzinga.com/files/images/story/2024/09/30/Wall-Street-dall_0.png?width=1200&height=800&fit=crop)
Via Benzinga · September 30, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 27, 2024
![](https://cdn.benzinga.com/files/images/story/2023/11/01/medicine-257349_12801.jpg?width=1200&height=800&fit=crop)
PLUS THERAPEUTICS, Inc. (NASDAQPSTV) shares are trading higher on Wednesday.
Via Benzinga · November 1, 2023
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
PSTV stock results show that Plus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 14, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
PSTV stock results show that Plus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 15, 2024
![](https://cdn.benzinga.com/files/images/story/2024/04/22/PSTV.png?width=1200&height=800&fit=crop)
Plus Therapeutics will secure $3 million in funding from the Department of Defense for pediatric brain cancer trial expansion.
Via Benzinga · April 22, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
PSTV stock results show that Plus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 5, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 20, 2023
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • NIO (NYSENIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
Via Benzinga · March 5, 2024
![](https://cdn.benzinga.com/files/images/story/2023/11/09/image18.jpg?width=1200&height=800&fit=crop)
The Dow Jones closed lower by around 40 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · November 9, 2023
![](https://cdn.benzinga.com/files/images/story/2023/11/01/image31_0.jpeg?width=1200&height=800&fit=crop)
Gainers
Via Benzinga · November 1, 2023
![](https://cdn.benzinga.com/files/images/story/2023/11/01/image21.jpeg?width=1200&height=800&fit=crop)
Gainers
Via Benzinga · November 1, 2023
![](https://investorplace.com/wp-content/uploads/2021/04/wall-street-washington-statue.jpg)
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!
Via InvestorPlace · November 1, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 31, 2023
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
Companies Reporting Before The Bell • BBVA (NYSEBBVA) is likely to report earnings for its third quarter. • BP NYSE:BPNYSEBP)
Via Benzinga · October 31, 2023
![](https://cdn.benzinga.com/files/images/story/2023/10/16/aapharma_5.png?width=1200&height=800&fit=crop)
Biocept Inc (NASDAQBIOC) filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware.
Via Benzinga · October 16, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · September 29, 2023
![](https://cdn.benzinga.com/files/images/story/2023/09/18/image34.jpeg?width=1200&height=800&fit=crop)
The Dow Jones closed lower by close to 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · September 18, 2023